Evaluation of Luminex xTAG Gastrointestinal Pathogen Panel Assay for Detection of Multiple Diarrheal Pathogens in Fecal Samples in Vietnam.

Diarrheal disease is a complex syndrome that remains a leading cause of global childhood morbidity and mortality. The diagnosis of enteric pathogens in a timely and precise manner is important for making treatment decisions and informing public health policy, but accurate diagnosis is a major challenge in industrializing countries. Multiplex molecular diagnostic techniques may represent a significant improvement over classical approaches. We evaluated the Luminex xTAG gastrointestinal pathogen panel (GPP) assay for the detection of common enteric bacterial and viral pathogens in Vietnam. Microbiological culture and real-time PCR were used as gold standards. The tests were performed on 479 stool samples collected from people admitted to the hospital for diarrheal disease throughout Vietnam. Sensitivity and specificity were calculated for the xTAG GPP for the seven principal diarrheal etiologies. The sensitivity and specificity for the xTAG GPP were >88% for Shigellaspp.,Campylobacterspp., rotavirus, norovirus genotype 1/2 (GI/GII), and adenovirus compared to those of microbiological culture and/or real-time PCR. However, the specificity was low (∼60%) for Salmonella species. Additionally, a number of important pathogens that are not identified in routine hospital procedures in this setting, such as Cryptosporidiumspp. and Clostridium difficile, were detected with the GPP. The use of the Luminex xTAG GPP for the detection of enteric pathogens in settings, like Vietnam, would dramatically improve the diagnostic accuracy and capacity of hospital laboratories, allowing for timely and appropriate therapy decisions and a wider understanding of the epidemiology of pathogens associated with severe diarrheal disease in low-resource settings

Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial

Background Trials of fluoxetine for recovery after stroke report conflicting results. The Assessment oF FluoxetINe In sTroke recoverY (AFFINITY) trial aimed to show if daily oral fluoxetine for 6 months after stroke improves functional outcome in an ethnically diverse population. Methods AFFINITY was a randomised, parallel-group, double-blind, placebo-controlled trial done in 43 hospital stroke units in Australia (n=29), New Zealand (four), and Vietnam (ten). Eligible patients were adults (aged ≥18 years) with a clinical diagnosis of acute stroke in the previous 2–15 days, brain imaging consistent with ischaemic or haemorrhagic stroke, and a persisting neurological deficit that produced a modified Rankin Scale (mRS) score of 1 or more. Patients were randomly assigned 1:1 via a web-based system using a minimisation algorithm to once daily, oral fluoxetine 20 mg capsules or matching placebo for 6 months. Patients, carers, investigators, and outcome assessors were masked to the treatment allocation. The primary outcome was functional status, measured by the mRS, at 6 months. The primary analysis was an ordinal logistic regression of the mRS at 6 months, adjusted for minimisation variables. Primary and safety analyses were done according to the patient's treatment allocation. The trial is registered with the Australian New Zealand Clinical Trials Registry, ACTRN12611000774921. Findings Between Jan 11, 2013, and June 30, 2019, 1280 patients were recruited in Australia (n=532), New Zealand (n=42), and Vietnam (n=706), of whom 642 were randomly assigned to fluoxetine and 638 were randomly assigned to placebo. Mean duration of trial treatment was 167 days (SD 48·1). At 6 months, mRS data were available in 624 (97%) patients in the fluoxetine group and 632 (99%) in the placebo group. The distribution of mRS categories was similar in the fluoxetine and placebo groups (adjusted common odds ratio 0·94, 95% CI 0·76–1·15; p=0·53). Compared with patients in the placebo group, patients in the fluoxetine group had more falls (20 [3%] vs seven [1%]; p=0·018), bone fractures (19 [3%] vs six [1%]; p=0·014), and epileptic seizures (ten [2%] vs two [<1%]; p=0·038) at 6 months. Interpretation Oral fluoxetine 20 mg daily for 6 months after acute stroke did not improve functional outcome and increased the risk of falls, bone fractures, and epileptic seizures. These results do not support the use of fluoxetine to improve functional outcome after stroke

Factors affecting synthesis of silver-nanoparticles and antimicrobial applications

Silver nanoparticles were synthesized from silver sulfate by using the chemical reduction method with dextran as both a reducing agent and a protective agent. The influence of reaction temperature, time, and initial pH on the synthesis was investigated. The formation of Ag nano-particles (AgNPs) and their morphology were characterized with UV-Vis spectroscopy, X-ray diffraction, scanning electron microscopy, energy dispersive X-ray analysis, and Fourier transform-infrared spectroscopy. The antifungal and antibacterial effects of AgNPs/dextran on Xanthomonas oryzae and Pyricularia oryzae were tested

Mutation c.307G>A in FUT1 gene has no effect on production performance of Yorkshire pigs in the tropics: the case of Vietnam

The alpha (1) fucosyltransferase gene (FUT1) is a candidate gene for controlling the adhesion of Escherichia coli F18 receptor. Indeed, a single-nucleotide polymorphism, c.307G>A, located in the gene is such that pigs with AA genotype are resistant to entero-toxigenic E. coli F18, whereas those with AG and GG genotypes are sensitive. An experiment was carried out in northern Vietnam from March 2016 to May 2017 to determine FUT1 genotype frequencies and the effect of these genotypes on production performance of Yorkshire pigs. A total of 613 animals were genotyped using polymerase chain reaction – restriction fragment length polymorphism method. The body weights at birth, weaning, initial fattening period, and final fattening period were collected from 611, 516, 479, and 418 animals, respectively, whereas backfat thickness, depth of longissimus dorsi, and lean meat percentage were recorded from 328 animals. The frequencies of FUT1 genotypes were found to be in Hardy–Weinberg equilibrium (P = 0.51). Effect of FUT1 genotype was not observed for all production traits (P > 0.05), whereas final body weight and depth of longissimus dorsi were significantly different between females and males (P < 0.05). These results suggest that selection of Yorkshire pigs resistant to entero-toxigenic E. coli F18 could be effective without adversely affecting average daily gain and lean meat.The accepted manuscript in pdf format is listed with the files at the bottom of this page. The presentation of the authors' names and (or) special characters in the title of the manuscript may differ slightly between what is listed on this page and what is listed in the pdf file of the accepted manuscript; that in the pdf file of the accepted manuscript is what was submitted by the author

Mutation c.307G>A in FUT1 gene has no effect on production performance of Yorkshire pigs in the tropics: the case of Vietnam

The alpha (1) fucosyltransferase gene (FUT1) is a candidate gene for controlling the adhesion of Escherichia Coli (E.coli) F18 receptor. Indeed, a Single Nucleotide Polymorphism (SNP), c.307G>A, located in the gene is such that pigs with AA genotype are resistant to Entero-Toxigenic E.coli (ETEC) F18 while those with AG and GG genotypes are sensitive. An experiment was carried out in northern Vietnam from March 2016 to May 2017 to determine FUT1 genotype frequencies and effect of this genotypes on production performance of Yorkshire pigs. A total of 613 animals were genotyped using Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. The body weights at birth, weaning, initial and final fattening period were collected from 611, 516, 479, 418 animals respectively while backfat thickness, depth of longissimus dorsi and lean meat percentage were recorded from 328 animals. The frequencies of FUT1 genotypes were found to be in Hardy-Weinberg equilibrium (P=0.51). Effect of FUT1 genotype was not observed for all production traits (P>0.05) while final body weight and depth of longissimus dorsi were significantly different between females and males (P<0.05). These results suggest that selection of Yorkshire pigs resistant to ETEC E18 could be effective without adversely affecting average daily gain and lean meat

Twelve-Month Outcomes of the AFFINITY Trial of Fluoxetine for Functional Recovery After Acute Stroke: AFFINITY Trial Steering Committee on Behalf of the AFFINITY Trial Collaboration

Background and Purpose: The AFFINITY trial (Assessment of Fluoxetine in Stroke Recovery) reported that oral fluoxetine 20 mg daily for 6 months after acute stroke did not improve functional outcome and increased the risk of falls, bone fractures, and seizures. After trial medication was ceased at 6 months, survivors were followed to 12 months post-randomization. This preplanned secondary analysis aimed to determine any sustained or delayed effects of fluoxetine at 12 months post-randomization. Methods: AFFINITY was a randomized, parallel-group, double-blind, placebo-controlled trial in adults (n=1280) with a clinical diagnosis of stroke in the previous 2 to 15 days and persisting neurological deficit who were recruited at 43 hospital stroke units in Australia (n=29), New Zealand (4), and Vietnam (10) between 2013 and 2019. Participants were randomized to oral fluoxetine 20 mg once daily (n=642) or matching placebo (n=638) for 6 months and followed until 12 months after randomization. The primary outcome was function, measured by the modified Rankin Scale, at 6 months. Secondary outcomes for these analyses included measures of the modified Rankin Scale, mood, cognition, overall health status, fatigue, health-related quality of life, and safety at 12 months. Results: Adherence to trial medication was for a mean 167 (SD 48) days and similar between randomized groups. At 12 months, the distribution of modified Rankin Scale categories was similar in the fluoxetine and placebo groups (adjusted common odds ratio, 0.93 [95% CI, 0.76–1.14]; P =0.46). Compared with placebo, patients allocated fluoxetine had fewer recurrent ischemic strokes (14 [2.18%] versus 29 [4.55%]; P =0.02), and no longer had significantly more falls (27 [4.21%] versus 15 [2.35%]; P =0.08), bone fractures (23 [3.58%] versus 11 [1.72%]; P =0.05), or seizures (11 [1.71%] versus 8 [1.25%]; P =0.64) at 12 months. Conclusions: Fluoxetine 20 mg daily for 6 months after acute stroke had no delayed or sustained effect on functional outcome, falls, bone fractures, or seizures at 12 months poststroke. The lower rate of recurrent ischemic stroke in the fluoxetine group is most likely a chance finding. REGISTRATION: URL: http://www.anzctr.org.au/ ; Unique identifier: ACTRN12611000774921